T 0400/97 (Immunoglobulins/CELLTECH) vom 24.05.2000
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2000:T040097.20000524
- Datum der Entscheidung
- 24. Mai 2000
- Aktenzeichen
- T 0400/97
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 84301996.9
- IPC-Klasse
- C12N 15/63
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Processes for the production of multichain polypeptides or proteins
- Name des Antragstellers
- Celltech Therapeutics Limited
- Name des Einsprechenden
- Boehringer Ingelheim GmbH
Genentech, Inc.
Eli Lilly and Company
Pharmacia & Upjohn AB
Protein Design Labs, Inc.
Roche Diagnostics GmbH - Kammer
- 3.3.04
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 83 1973European Patent Convention Art 87 1973European Patent Convention Art 88 1973
- Schlagwörter
- Oral presentation - state of the art (no)
Main request - sufficiency of disclosure (no)
First auxiliary request - sufficiency of disclosure (yes)
First auxiliary request - priority right (yes)
First auxiliary request - novelty and inventive step (yes)-not disputed - Orientierungssatz
- The information content made publicly available by a lecture cannot be put beyond reasonable doubt by any evidence of the lecturer alone, as the lecturer is in a quite different position to a member of the audience (see point 3 ff).
- Zitierende Akten
- T 1212/97
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside
2. The case is remitted to the first instance with the order to maintain the patent on the basis of the set of claims and description submitted as first auxiliary request on 24 May 2000 and the drawings as granted.